世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

遺伝子毒性学 - 世界市場シェアとランキング、全体売上高と需要予測 2025-2031

遺伝子毒性学 - 世界市場シェアとランキング、全体売上高と需要予測 2025-2031


Genetic Toxicology - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

遺伝子毒性学の世界市場は、2024年には2350億7000万米ドル規模と推定され、2031年には3446億5000万米ドルに再調整され、予測期間2025-2031年のCAGRは5.7%と予測されている。 遺伝毒性学は毒性学の一分野であり、... もっと見る

 

 

出版社 出版年月 電子版価格 納期 言語
QYResearch
QYリサーチ
2025年2月7日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
5-7営業日 英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

遺伝子毒性学の世界市場は、2024年には2350億7000万米ドル規模と推定され、2031年には3446億5000万米ドルに再調整され、予測期間2025-2031年のCAGRは5.7%と予測されている。
遺伝毒性学は毒性学の一分野であり、様々な物理的、化学的、生物学的薬剤によって引き起こされる遺伝的損傷や突然変異の研究に焦点を当てている。これらの薬剤はしばしば遺伝毒性薬剤と呼ばれ、DNAを含む細胞内の遺伝物質を変化させ、突然変異やその他の遺伝的変化を引き起こす可能性がある。遺伝子毒性学は、医薬品、化学物質、環境汚染物質、放射線など様々な物質の安全性を評価する上で重要な分野である。

規制当局の監視強化:世界中の規制機関は、医薬品、化学物質、各種製品の安全性を評価する上で、遺伝子毒性検査の重要性を強調し続けている。規制の進展に伴い、このような検査に対する需要は今後も高水準で推移すると思われる。
検査法の進歩:遺伝子毒性学の分野では、検査方法や技術が進歩している。これには、より高感度で特異的なアッセイの開発、ハイスループットスクリーニング、3D細胞培養モデルの使用などが含まれ、検査の精度と効率が向上している。

体外試験への需要の高まり:動物実験の必要性を減らし、より迅速で費用対効果の高い結果を提供できる試験管内(試験管または細胞ベース)遺伝毒性試験へのシフトが進んでいる。これは、動物実験を減らすという広範な傾向と一致している。
ゲノムデータの評価:ゲノムデータの利用可能性が高まるにつれて、遺伝毒性学的研究にゲノミクスとバイオインフォマティクスを統合する傾向がある。これにより、毒性機序のより深い理解と遺伝学的バイオマーカーの同定が可能となる。
本レポートは、遺伝毒性学の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の遺伝毒性学の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。
遺伝子毒性学市場の規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量分析および定性分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、遺伝毒性学に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
フロンテッジラボラトリーズ
アクセラ
チャールズ・リバー
ファーマロン
ラボコープ
シンジェン
ビボテクニア
テクニクス
オーリゲン・ファーマシューティカル・サービス
ERBCグループ
ネクストジェン
カーディナル・ヘルス
トキシス
アボットトキシコロジー
エボテック
EPL
タイプ別セグメント
遺伝毒性スクリーニングアッセイ
GLP標準遺伝毒性アッセイ
アプリケーション別セグメント
ミニAmes/Ames
遺伝子突然変異
インビトロ小核
染色体異常
その他
地域別
北米
米国
カナダ
アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア太平洋地域
ヨーロッパ
ドイツ
フランス
英国
イタリア
オランダ
北欧諸国
その他のヨーロッパ
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他のMEA

各章の概要
第1章: レポートのスコープ、世界の総市場規模を紹介します。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:遺伝毒性学企業の競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:様々な市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展の可能性を網羅し、読者が様々な市場セグメントにおけるブルーオーシャン市場を見つけるのに役立つ。
第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場でブルーオーシャン市場を見つけるのを助ける。
第5章:地域レベルでの遺伝毒性学の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。
第6章:国レベルでの遺伝毒性学の収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Genetic Toxicology Product Introduction
1.2 Global Genetic Toxicology Market Size Forecast (2020-2031)
1.3 Genetic Toxicology Market Trends & Drivers
1.3.1 Genetic Toxicology Industry Trends
1.3.2 Genetic Toxicology Market Drivers & Opportunity
1.3.3 Genetic Toxicology Market Challenges
1.3.4 Genetic Toxicology Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Genetic Toxicology Players Revenue Ranking (2024)
2.2 Global Genetic Toxicology Revenue by Company (2020-2025)
2.3 Key Companies Genetic Toxicology Manufacturing Base Distribution and Headquarters
2.4 Key Companies Genetic Toxicology Product Offered
2.5 Key Companies Time to Begin Mass Production of Genetic Toxicology
2.6 Genetic Toxicology Market Competitive Analysis
2.6.1 Genetic Toxicology Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Genetic Toxicology Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Toxicology as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Genotoxicity Screening Assays
3.1.2 GLP Standard Genotoxicity Assays
3.2 Global Genetic Toxicology Sales Value by Type
3.2.1 Global Genetic Toxicology Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Genetic Toxicology Sales Value, by Type (2020-2031)
3.2.3 Global Genetic Toxicology Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Mini Ames/Ames
4.1.2 Gene Mutation
4.1.3 In Vitro Micronucleus
4.1.4 Chromosome Aberration
4.1.5 Others
4.2 Global Genetic Toxicology Sales Value by Application
4.2.1 Global Genetic Toxicology Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Genetic Toxicology Sales Value, by Application (2020-2031)
4.2.3 Global Genetic Toxicology Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Genetic Toxicology Sales Value by Region
5.1.1 Global Genetic Toxicology Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Genetic Toxicology Sales Value by Region (2020-2025)
5.1.3 Global Genetic Toxicology Sales Value by Region (2026-2031)
5.1.4 Global Genetic Toxicology Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Genetic Toxicology Sales Value, 2020-2031
5.2.2 North America Genetic Toxicology Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Genetic Toxicology Sales Value, 2020-2031
5.3.2 Europe Genetic Toxicology Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Genetic Toxicology Sales Value, 2020-2031
5.4.2 Asia Pacific Genetic Toxicology Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Genetic Toxicology Sales Value, 2020-2031
5.5.2 South America Genetic Toxicology Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Genetic Toxicology Sales Value, 2020-2031
5.6.2 Middle East & Africa Genetic Toxicology Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Genetic Toxicology Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Genetic Toxicology Sales Value, 2020-2031
6.3 United States
6.3.1 United States Genetic Toxicology Sales Value, 2020-2031
6.3.2 United States Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Genetic Toxicology Sales Value, 2020-2031
6.4.2 Europe Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Genetic Toxicology Sales Value, 2020-2031
6.5.2 China Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.5.3 China Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Genetic Toxicology Sales Value, 2020-2031
6.6.2 Japan Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Genetic Toxicology Sales Value, 2020-2031
6.7.2 South Korea Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Genetic Toxicology Sales Value, 2020-2031
6.8.2 Southeast Asia Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Genetic Toxicology Sales Value, 2020-2031
6.9.2 India Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.9.3 India Genetic Toxicology Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Frontage Laboratories
7.1.1 Frontage Laboratories Profile
7.1.2 Frontage Laboratories Main Business
7.1.3 Frontage Laboratories Genetic Toxicology Products, Services and Solutions
7.1.4 Frontage Laboratories Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.1.5 Frontage Laboratories Recent Developments
7.2 Accelera
7.2.1 Accelera Profile
7.2.2 Accelera Main Business
7.2.3 Accelera Genetic Toxicology Products, Services and Solutions
7.2.4 Accelera Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.2.5 Accelera Recent Developments
7.3 Charles River
7.3.1 Charles River Profile
7.3.2 Charles River Main Business
7.3.3 Charles River Genetic Toxicology Products, Services and Solutions
7.3.4 Charles River Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.3.5 Charles River Recent Developments
7.4 Pharmaron
7.4.1 Pharmaron Profile
7.4.2 Pharmaron Main Business
7.4.3 Pharmaron Genetic Toxicology Products, Services and Solutions
7.4.4 Pharmaron Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.4.5 Pharmaron Recent Developments
7.5 Labcorp
7.5.1 Labcorp Profile
7.5.2 Labcorp Main Business
7.5.3 Labcorp Genetic Toxicology Products, Services and Solutions
7.5.4 Labcorp Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.5.5 Labcorp Recent Developments
7.6 Syngene
7.6.1 Syngene Profile
7.6.2 Syngene Main Business
7.6.3 Syngene Genetic Toxicology Products, Services and Solutions
7.6.4 Syngene Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.6.5 Syngene Recent Developments
7.7 Vivotecnia
7.7.1 Vivotecnia Profile
7.7.2 Vivotecnia Main Business
7.7.3 Vivotecnia Genetic Toxicology Products, Services and Solutions
7.7.4 Vivotecnia Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.7.5 Vivotecnia Recent Developments
7.8 Technics
7.8.1 Technics Profile
7.8.2 Technics Main Business
7.8.3 Technics Genetic Toxicology Products, Services and Solutions
7.8.4 Technics Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.8.5 Technics Recent Developments
7.9 Aurigene Pharmaceutical Services
7.9.1 Aurigene Pharmaceutical Services Profile
7.9.2 Aurigene Pharmaceutical Services Main Business
7.9.3 Aurigene Pharmaceutical Services Genetic Toxicology Products, Services and Solutions
7.9.4 Aurigene Pharmaceutical Services Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.9.5 Aurigene Pharmaceutical Services Recent Developments
7.10 ERBC Group
7.10.1 ERBC Group Profile
7.10.2 ERBC Group Main Business
7.10.3 ERBC Group Genetic Toxicology Products, Services and Solutions
7.10.4 ERBC Group Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.10.5 ERBC Group Recent Developments
7.11 NextGen
7.11.1 NextGen Profile
7.11.2 NextGen Main Business
7.11.3 NextGen Genetic Toxicology Products, Services and Solutions
7.11.4 NextGen Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.11.5 NextGen Recent Developments
7.12 Cardinal Health
7.12.1 Cardinal Health Profile
7.12.2 Cardinal Health Main Business
7.12.3 Cardinal Health Genetic Toxicology Products, Services and Solutions
7.12.4 Cardinal Health Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.12.5 Cardinal Health Recent Developments
7.13 Toxys
7.13.1 Toxys Profile
7.13.2 Toxys Main Business
7.13.3 Toxys Genetic Toxicology Products, Services and Solutions
7.13.4 Toxys Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.13.5 Toxys Recent Developments
7.14 Abbott Toxicology
7.14.1 Abbott Toxicology Profile
7.14.2 Abbott Toxicology Main Business
7.14.3 Abbott Toxicology Genetic Toxicology Products, Services and Solutions
7.14.4 Abbott Toxicology Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.14.5 Abbott Toxicology Recent Developments
7.15 Evotec
7.15.1 Evotec Profile
7.15.2 Evotec Main Business
7.15.3 Evotec Genetic Toxicology Products, Services and Solutions
7.15.4 Evotec Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.15.5 Evotec Recent Developments
7.16 EPL
7.16.1 EPL Profile
7.16.2 EPL Main Business
7.16.3 EPL Genetic Toxicology Products, Services and Solutions
7.16.4 EPL Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.16.5 EPL Recent Developments
8 Industry Chain Analysis
8.1 Genetic Toxicology Industrial Chain
8.2 Genetic Toxicology Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Genetic Toxicology Sales Model
8.5.2 Sales Channel
8.5.3 Genetic Toxicology Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

The global market for Genetic Toxicology was estimated to be worth US$ 235070 million in 2024 and is forecast to a readjusted size of US$ 344650 million by 2031 with a CAGR of 5.7% during the forecast period 2025-2031.
Genetic toxicology is a branch of toxicology that focuses on the study of the genetic damage or mutations caused by various physical, chemical, and biological agents. These agents, often referred to as genotoxic agents, have the potential to alter the genetic material within cells, including DNA, which can lead to mutations or other genetic changes. Genetic toxicology is an important field for assessing the safety of various substances, including pharmaceuticals, chemicals, environmental pollutants, and radiation.

Increased Regulatory Scrutiny: Regulatory agencies worldwide continue to emphasize the importance of genetic toxicology testing in assessing the safety of pharmaceuticals, chemicals, and various products. The demand for such testing is likely to remain high as regulations evolve.
Advancements in Testing Methods: The field of genetic toxicology has seen advances in testing methods and technologies. This includes the development of more sensitive and specific assays, high-throughput screening, and the use of 3D cell culture models, which enhance the accuracy and efficiency of testing.

Growing Demand for In Vitro Testing: There"s a shift toward in vitro (test tube or cell-based) genetic toxicology testing, which can reduce the need for animal testing and offer faster and more cost-effective results. This is in line with broader trends in reducing animal testing.
Assessment of Genomic Data: With the increasing availability of genomic data, there"s a trend toward integrating genomics and bioinformatics into genetic toxicology studies. This allows for a deeper understanding of mechanisms and the identification of genetic biomarkers for toxicity.
This report aims to provide a comprehensive presentation of the global market for Genetic Toxicology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Genetic Toxicology by region & country, by Type, and by Application.
The Genetic Toxicology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genetic Toxicology.

Market Segmentation
By Company
Frontage Laboratories
Accelera
Charles River
Pharmaron
Labcorp
Syngene
Vivotecnia
Technics
Aurigene Pharmaceutical Services
ERBC Group
NextGen
Cardinal Health
Toxys
Abbott Toxicology
Evotec
EPL
Segment by Type
Genotoxicity Screening Assays
GLP Standard Genotoxicity Assays
Segment by Application
Mini Ames/Ames
Gene Mutation
In Vitro Micronucleus
Chromosome Aberration
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Genetic Toxicology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Genetic Toxicology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Genetic Toxicology in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Genetic Toxicology Product Introduction
1.2 Global Genetic Toxicology Market Size Forecast (2020-2031)
1.3 Genetic Toxicology Market Trends & Drivers
1.3.1 Genetic Toxicology Industry Trends
1.3.2 Genetic Toxicology Market Drivers & Opportunity
1.3.3 Genetic Toxicology Market Challenges
1.3.4 Genetic Toxicology Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Genetic Toxicology Players Revenue Ranking (2024)
2.2 Global Genetic Toxicology Revenue by Company (2020-2025)
2.3 Key Companies Genetic Toxicology Manufacturing Base Distribution and Headquarters
2.4 Key Companies Genetic Toxicology Product Offered
2.5 Key Companies Time to Begin Mass Production of Genetic Toxicology
2.6 Genetic Toxicology Market Competitive Analysis
2.6.1 Genetic Toxicology Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Genetic Toxicology Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Toxicology as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Genotoxicity Screening Assays
3.1.2 GLP Standard Genotoxicity Assays
3.2 Global Genetic Toxicology Sales Value by Type
3.2.1 Global Genetic Toxicology Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Genetic Toxicology Sales Value, by Type (2020-2031)
3.2.3 Global Genetic Toxicology Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Mini Ames/Ames
4.1.2 Gene Mutation
4.1.3 In Vitro Micronucleus
4.1.4 Chromosome Aberration
4.1.5 Others
4.2 Global Genetic Toxicology Sales Value by Application
4.2.1 Global Genetic Toxicology Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Genetic Toxicology Sales Value, by Application (2020-2031)
4.2.3 Global Genetic Toxicology Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Genetic Toxicology Sales Value by Region
5.1.1 Global Genetic Toxicology Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Genetic Toxicology Sales Value by Region (2020-2025)
5.1.3 Global Genetic Toxicology Sales Value by Region (2026-2031)
5.1.4 Global Genetic Toxicology Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Genetic Toxicology Sales Value, 2020-2031
5.2.2 North America Genetic Toxicology Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Genetic Toxicology Sales Value, 2020-2031
5.3.2 Europe Genetic Toxicology Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Genetic Toxicology Sales Value, 2020-2031
5.4.2 Asia Pacific Genetic Toxicology Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Genetic Toxicology Sales Value, 2020-2031
5.5.2 South America Genetic Toxicology Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Genetic Toxicology Sales Value, 2020-2031
5.6.2 Middle East & Africa Genetic Toxicology Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Genetic Toxicology Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Genetic Toxicology Sales Value, 2020-2031
6.3 United States
6.3.1 United States Genetic Toxicology Sales Value, 2020-2031
6.3.2 United States Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Genetic Toxicology Sales Value, 2020-2031
6.4.2 Europe Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Genetic Toxicology Sales Value, 2020-2031
6.5.2 China Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.5.3 China Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Genetic Toxicology Sales Value, 2020-2031
6.6.2 Japan Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Genetic Toxicology Sales Value, 2020-2031
6.7.2 South Korea Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Genetic Toxicology Sales Value, 2020-2031
6.8.2 Southeast Asia Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Genetic Toxicology Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Genetic Toxicology Sales Value, 2020-2031
6.9.2 India Genetic Toxicology Sales Value by Type (%), 2024 VS 2031
6.9.3 India Genetic Toxicology Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Frontage Laboratories
7.1.1 Frontage Laboratories Profile
7.1.2 Frontage Laboratories Main Business
7.1.3 Frontage Laboratories Genetic Toxicology Products, Services and Solutions
7.1.4 Frontage Laboratories Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.1.5 Frontage Laboratories Recent Developments
7.2 Accelera
7.2.1 Accelera Profile
7.2.2 Accelera Main Business
7.2.3 Accelera Genetic Toxicology Products, Services and Solutions
7.2.4 Accelera Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.2.5 Accelera Recent Developments
7.3 Charles River
7.3.1 Charles River Profile
7.3.2 Charles River Main Business
7.3.3 Charles River Genetic Toxicology Products, Services and Solutions
7.3.4 Charles River Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.3.5 Charles River Recent Developments
7.4 Pharmaron
7.4.1 Pharmaron Profile
7.4.2 Pharmaron Main Business
7.4.3 Pharmaron Genetic Toxicology Products, Services and Solutions
7.4.4 Pharmaron Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.4.5 Pharmaron Recent Developments
7.5 Labcorp
7.5.1 Labcorp Profile
7.5.2 Labcorp Main Business
7.5.3 Labcorp Genetic Toxicology Products, Services and Solutions
7.5.4 Labcorp Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.5.5 Labcorp Recent Developments
7.6 Syngene
7.6.1 Syngene Profile
7.6.2 Syngene Main Business
7.6.3 Syngene Genetic Toxicology Products, Services and Solutions
7.6.4 Syngene Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.6.5 Syngene Recent Developments
7.7 Vivotecnia
7.7.1 Vivotecnia Profile
7.7.2 Vivotecnia Main Business
7.7.3 Vivotecnia Genetic Toxicology Products, Services and Solutions
7.7.4 Vivotecnia Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.7.5 Vivotecnia Recent Developments
7.8 Technics
7.8.1 Technics Profile
7.8.2 Technics Main Business
7.8.3 Technics Genetic Toxicology Products, Services and Solutions
7.8.4 Technics Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.8.5 Technics Recent Developments
7.9 Aurigene Pharmaceutical Services
7.9.1 Aurigene Pharmaceutical Services Profile
7.9.2 Aurigene Pharmaceutical Services Main Business
7.9.3 Aurigene Pharmaceutical Services Genetic Toxicology Products, Services and Solutions
7.9.4 Aurigene Pharmaceutical Services Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.9.5 Aurigene Pharmaceutical Services Recent Developments
7.10 ERBC Group
7.10.1 ERBC Group Profile
7.10.2 ERBC Group Main Business
7.10.3 ERBC Group Genetic Toxicology Products, Services and Solutions
7.10.4 ERBC Group Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.10.5 ERBC Group Recent Developments
7.11 NextGen
7.11.1 NextGen Profile
7.11.2 NextGen Main Business
7.11.3 NextGen Genetic Toxicology Products, Services and Solutions
7.11.4 NextGen Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.11.5 NextGen Recent Developments
7.12 Cardinal Health
7.12.1 Cardinal Health Profile
7.12.2 Cardinal Health Main Business
7.12.3 Cardinal Health Genetic Toxicology Products, Services and Solutions
7.12.4 Cardinal Health Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.12.5 Cardinal Health Recent Developments
7.13 Toxys
7.13.1 Toxys Profile
7.13.2 Toxys Main Business
7.13.3 Toxys Genetic Toxicology Products, Services and Solutions
7.13.4 Toxys Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.13.5 Toxys Recent Developments
7.14 Abbott Toxicology
7.14.1 Abbott Toxicology Profile
7.14.2 Abbott Toxicology Main Business
7.14.3 Abbott Toxicology Genetic Toxicology Products, Services and Solutions
7.14.4 Abbott Toxicology Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.14.5 Abbott Toxicology Recent Developments
7.15 Evotec
7.15.1 Evotec Profile
7.15.2 Evotec Main Business
7.15.3 Evotec Genetic Toxicology Products, Services and Solutions
7.15.4 Evotec Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.15.5 Evotec Recent Developments
7.16 EPL
7.16.1 EPL Profile
7.16.2 EPL Main Business
7.16.3 EPL Genetic Toxicology Products, Services and Solutions
7.16.4 EPL Genetic Toxicology Revenue (US$ Million) & (2020-2025)
7.16.5 EPL Recent Developments
8 Industry Chain Analysis
8.1 Genetic Toxicology Industrial Chain
8.2 Genetic Toxicology Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Genetic Toxicology Sales Model
8.5.2 Sales Channel
8.5.3 Genetic Toxicology Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療/ヘルスケア)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/02/21 10:27

150.86 円

158.69 円

193.74 円

ページTOPに戻る